Common Misconceptions and Why Headlines Get This Wrong Misconception #1: The Warning Applies to All Thyroid Cancers Reality: The FDA warning is specifically for MTC and MEN2
Head, [email protected] This article was submitted to Striated Muscle Physiology, a section of the journal Frontiers in Physiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
All procedures were approved by the University of Washington Institutional Animal Care and Use Committee (IACUC Protocol 409101)
A recent press release reported topline results indicating that tirzepatide met the primary objective of noninferiority compared with dulaglutide for time to first occurrence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke (HR 0.92, 95.3% CI 0.831.01), along with a reduction in all-cause mortality (HR 0.84, 95% CI 0.750.94)
PBMC, peripheral blood monouclear cell